drugset

drugset / Trial / NCT01797419

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

NCT01797419 ↗

Phase 1 Withdrawn Gilead Sciences

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.

Timeline

Start: 2013-05
Primary completion: 2013-08
Completion: 2013-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Presatovir	Small molecule	0.5 unknown	Oral

Indications